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APOBEC3G (A3G) is an antiretroviral host factor that
functions by deaminating dC to dU in retroviral cDNA
[1–5]. HIV-1 Vif protein counteracts A3G via a ubiqui-
tin-proteasome pathway [6–12]. In the case of a simple
retrovirus such as the murine leukemia virus (MLV), it
remains unclear why it can replicate in cells express-
ing APOBEC3 (A3) even though it doesn’t possess any
accessory proteins such as Vif [2, 13]. In this study, we
demonstrate that MLV escapes from murine A3 (mA3)
via two distinct novel mechanisms. First, viral RNA
(vRNA) blocks the binding of mA3 to Gag, resulting
in the exclusion of mA3 from MLV virions. Second,
viral protease (vPR) cleaves mA3 after maturation of
virions. Here, we suggest that each virus has its own
strategy to escape from A3 proteins and that these
mechanisms might be used by other viruses that do
not possess Vif-like protein. On the other hand, mice
possess another form of mA3, Dexon5, that escapes
from the cleavage by vPR to show more antiviral activ-
ity than the wild type mA3. This also suggests that bat-
tles between host intrinsic immunity and viruses have
led to the evolution of proteins on both sides.
Results and Discussion
vRNA Specifically Blocked the mA3 Incorporation
into MLV Virions by Inhibiting Its Binding to Gag
Nucleocapsid Protein
We previously reported that mA3 could not inhibit MLV
because it was specifically excluded from MLV virions
[13]. To elucidate this mechanism, we first tested the in-
teraction of mA3 with MLV Gag because human A3G
(hA3G) had been reported to bind HIV-1 Gag Nucleocap-
sid (NC) for its incorporation into HIV-1 virions [14–18].
Immunoprecipitation assays clearly demonstrated that
mA3 as well as hA3G could bind to the p65 Gag precursor
protein (p65Gag) (Figure 1A). GST pull-down assays also
showed that GST-MLV Gag NC efficiently precipitated
mA3, as well as hA3G, to similar extents (Figure S1A).
These results were apparently different from those re-
ported by the Cullen laboratory, which demonstrated
*Correspondence: atakaori@kuhp.kyoto-u.ac.jpthat this specific exclusion is attributed to the inability
of mA3 to bind MLV Gag [19]. We assume that this dis-
crepancy might originate from the difference in GST-fu-
sion proteins that each study used. Furthermore, when
we prepared virus-like particles (VLPs) without transfer
vectors, we clearly detected the mA3 incorporation into
MLV VLPs (Figure 1B, lane 8). These data indicate that
mA3 can be incorporated into MLV VLPs by binding to
MLV Gag NC as seen with HIV-1.
Because MLV VLPs could efficiently package mA3
whereas MLV virion excluded it, we suspected that
vRNA might block the mA3 incorporation. Expression
of vRNA efficiently reduced the mA3 incorporation into
MLV virions while barely affecting that into HIV-1 virions
(Figure 1B). In contrast, expression of vRNA slightly
reduced the hA3G incorporation into MLV virions but
not into HIV-1 virions. Dose-escalation studies revealed
that expression of MLV vRNA inhibited the incorporation
of hA3G and mA3 into MLV virions in a dose-dependent
manner, and the exclusion of mA3 from virions was
much stronger than that of hA3G from virions (Figure 1C).
In contrast, expression of HIV-1 vRNA facilitated the
hA3G incorporation into HIV-1 virions as previously re-
ported [16–18], whereas it did not affect the mA3 incor-
poration into HIV-1 virions (Figure 1D). These findings
suggest that the exclusion of APOBEC3 by vRNA is spe-
cifically detected in MLV virions. To further investigate
the mechanism, we tested several transfer vectors with
different RNA-packaging capacities (Figure 1E). Compa-
rable levels of luciferase expression in producer cells sug-
gested that comparable levels of vRNA and mRNA were
transcribed (data not shown). Luciferase activities in tar-
get cells demonstrated that only vRNA produced with
pDON/Luc was efficiently packaged into MLV virions. Re-
duced luciferaseactivities with more transfer vectors from
a certain point was seen even without mA3, suggesting
that too many transfer vectors affect the retroviral titer
itself (data not shown). Only cotransfection of pDON/Luc
efficiently excluded mA3 from MLV virions in a dose-
dependent manner, indicating that only packagable
RNA could exclude mA3 from MLV virions. This suggests
that the ability of vRNA to bind to MLV Gag clearly corre-
lates with the capacity of MLV virions to exclude mA3.
Finally, we examined the effect of vRNA on the binding
of mA3 to MLV Gag. Immunoprecipitation and GST pull-
down assays in the presence of vRNA revealed that ex-
pression of vRNA clearly reduced the binding of mA3 to
Gag more efficiently than it reduced hA3G binding to
Gag (Figure 1A, lanes 5 and 6 and Figure S1A, lane 4),
which corresponded to the extent of these proteins’ ex-
clusion from MLV virions (Figure 1C). These findings indi-
cate that vRNA specifically blocks the incorporation of
mA3 into MLV virions by inhibiting its binding to Gag
NC. In addition, we performed GST pull-down assays
with RNase treatment, but RNase treatment eliminated
all the binding of mA3 to Gag; this result suggested
that the binding of mA3 to Gag was RNA dependent
(Figure S1B).
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1566Figure 1. vRNA Blocked mA3 Incorporation into MLV virions by Inhibiting its Binding to MLV Gag
(A) MLV Gag protein bound to mA3 as well as hA3G and vRNA inhibited this binding. Expression vectors for HA-hA3G or HA-mA3 were cotrans-
fected with pMLVg/p in the presence (+) or absence (2) of transfer vector pDON/Luc. Complexes were immunoprecipitated with HA polyclonal
antibody and subjected to immunoblot with MLV Gag (top panel) or HA (bottom panel) mAbs. In the absence of transfer vectors, both hA3G and
mA3 coprecipitated p65Gag (lanes 11 and 12, respectively), whereas cotransfection of transfer vectors reduced the binding of A3 to p65Gag (lanes
5 and 6). An arrow indicates p65Gag, a filled arrowhead indicates mA3, and an open arrowhead indicates hA3G.
(B) MLV VLPs efficiently packaged mA3, but MLV virions did not. HIV-1 vector (vHIV-1) virus and its VLPs were prepared by cotransfection of
pMDLg/p plus pVSV-G and pRSV-Rev with pcDNA3/HA-hA3G or pcDNA3/HA-mA3 in the presence (+) or absence (2) of transfer vector
pCSII/Luc, respectively. MLV and its VLPs were also prepared by cotransfection of pMLVg/p plus pVSV-G with pcDNA3/HA-hA3G or
pcDNA3/HA-mA3 in the presence (+) or absence (2) of transfer vector pDON/Luc, respectively. Precipitated virions and VLPs were subjected
to immunoblotting with HA mAb (top panel) and with p24 mAb for HIV-1 and MLV Gag mAb for MLV (bottom panel). An arrow indicates p30CA.
(C) Cotransfection of MLV transfer vectors reduced the incorporation of hA3G and mA3 into MLV virions in a dose-dependent manner and in-
hibited the incorporation of mA3 into MLV virion more efficiently than it inhibited incorporation of hA3G. MLV virions were prepared by cotrans-
fection of pMLVg/p plus pVSV-G with 30 ng of pcDNA3/HA-hA3G or pcDNA3/HA-mA3 in the presence of increasing amounts of MLV transfer
vector pDON/Luc (with control vectors making up the balance). Precipitated virions were subjected to immunoblotting with HA (top panel)
and MLV Gag mAbs (middle panel). Cell lysates were also subjected to immunoblotting with HA mAb (bottom panel).
(D) Cotransfection of HIV-1 transfer vectors facilitated the incorporation of hA3G into HIV-1 virion, but it did not affect incorporation of mA3 into
HIV-1 virion. vHIV-1 virions were prepared by cotransfection of pMDLg/p plus pVSV-G with 30 ng of pcDNA3/HA-hA3G or pcDNA3/HA-mA3 in the
presence of increasing amounts of HIV-1 transfer vector pCSII/Luc (with control vectors making up the balance). Precipitated virions were sub-
jected to immunoblotting with HA (top panel) and p24 mAbs (middle panel). Cell lysates were also subjected to immunoblotting with HA mAb
(bottom panel). An arrow indicates p24CA.
(E) Only packagable RNA blocked the mA3 incorporation into virions. MLV virions were prepared by cotransfection of pMLVg/p and pVSV-G plus
pcDNA3/HA-mA3 with different transfer vectors (pDON/Luc, pDON/Dc/Luc, pCSII/Luc, and pGL3-control). Luciferase activities of target cell
lysates challenged with the produced virions (top panel) were measured as indicated. Precipitated virions were subjected to immunoblotting
with HA (middle panel) and MLV Gag mAbs (bottom panel). An arrow indicates p30CA.vPR Cleaves mA3
When we prepared VLPs, we detected, in addition to the
52 kDa full-length form, a protein band with an approxi-
mate molecular weight of 32 kDa (Figure S2A, lane 6).
Similar experiments with mA3 containing different tags
also showed similar results (Figure S2B), suggesting
that mA3 might be cleaved into approximately 30 kDa
N-terminal and 25 kDa C-terminal fragments in MLV
VLPs. HIV-1 also contained this fragment but HTLV-1did not, suggesting the specificity of this cleavage
(Figure 2A).
The existence of a truncated form of mA3 that is only
detected in VLPs prompted us to test the possible
involvement of vPR. We examined the presence of this
truncated form in VLPs that was prepared with several
mutants of packaging plasmids (Figure 2B). The pres-
ence of a truncated mA3 was supported by the exis-
tence of the p30 product of Gag (p30CA) (Figure 2C).
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1567Figure 2. mA3 Was Cleaved in MLV and HIV-1 Virions, and vPR Was Involved in the Cleavage of mA3
(A) Small products of mA3 were specifically detected in MLV and HIV-1 but not in HTLV-1. Viruses were prepared by transfection with pMLVg/p
plus pVSV-G for MLV, pNL43/DEnvDvif-Luc plus pVSV-G for pHIV-1, or K30 for HTLV-1 with pcDNA3/HA-hA3G or pcDNA3/HA-mA3. Precipitated
virions (top panel) and cell lysates (middle panel) were subjected to immunoblotting with HA mAb.
Precipitated virions were also subjected to immunoblotting with MLV Gag mAb for MLV, p24 mAb for HIV-1, and HTLV-1 Gag mAb for HTLV-1
(bottom panel). A filled arrowhead indicates mA3; an open arrowhead indicates hA3G; a filled arrowhead with an asterisk indicates a small frag-
ment of mA3; an open arrowhead with an asterisk indicates a small fragment of hA3G; and an arrow indicates p30CA (lanes 1–3), p24CA (lanes 4–6),
and p19CA (lanes 7–9).
(B) A schematic figure of pMLVg/p and its mutants.
(C) Cleavage of mA3 corresponded to the cleavage of Gag. MLV VLPs were prepared by cotransfection of pMLVg/p or its mutants (pMLVg/pr/rt,
pMLVg/pr, and pMLVg) plus pVSV-G with pcDNA3/HA-mA3. Precipitated VLPs were subjected to immunoblotting with HA (top panel) and MLV
Gag (bottom panel) mAbs. A filled arrowhead indicates mA3; a filled arrowhead with an asterisk indicates a truncated form of mA3; an arrow
indicates p65Gag; and an arrow with an asterisk indicates p30CA.
(D) Protease inhibitors specifically blocked the cleavage of mA3 as well as the cleavage of Gag. MLV VLPs and pHIV-1 were prepared as
described above and treated with protease inhibitors as indicated. Precipitated VLPs and virions were subjected to immunoblotting with HA
mAb (top panel) and MLV Gag mAb for MLV or p24 mAb for HIV-1 (bottom panel). A filled arrowhead indicates mA3; a filled arrowhead with
an asterisk indicates a truncated form of mA3; an arrow indicates p65Gag for MLV and p55Gag for HIV-1, respectively; and an arrow with an asterisk
indicates p30CA for MLV and p24CA for HIV-1, respectively. APV, amprenavir; LPV, lopinavir; IDV, indinavir sulfate; ATV, atanazavir sulfate; RTV,
ritonavir; NFV, nelfinavir; SQV, saquinavir.
(E) APV blocked the cleavage of mA3 but not the cleavage of hA3G. MLV VLPs and pHIV-1 were prepared as described above and treated with
APV as indicated. A filled arrowhead indicates mA3; a filled arrowhead with an asterisk indicates a truncated form of mA3; an open arrowhead
indicates hA3G; an open arrowhead with an asterisk indicates a truncated form of hA3G; an arrow indicates p65Gag for MLV and p55Gag for HIV-1,
respectively; and an arrow with an asterisk indicates p30CA for MLV and p24CA for HIV-1, respectively.We suspect that the introduction of a stop codon at the
initiation of the coding sequence of RT might affect the
enzymatic activity of vPR and result in a small amount
of a truncated form and p30CA. We further examined
the assay in the presence of several HIV-1 PR inhibitors
(PIs). All the PIs showed anti-HIV-1 PR activity as ex-
pected, whereas only APV and ATV could block the ac-
tivity of MLV PR (Figure 2D, bottom panel). In parallel, all
the PIs inhibited the appearance of a truncated form of
mA3 in HIV-1, whereas treatment with APV and ATV
only showed the disappearance of a truncated form in
MLV (Figure 2D, top panel). These data indicate that
the truncated form in VLP is a cleaved product of mA3
and that vPR is involved in this cleavage. In contrast,a small product of hA3G was detected even in cell lysate
(Figure 2A), and treatment with APV could not reduce
this product of hA3G in MLV and HIV-1. These results
suggest that this product was made in producer cells
and incorporated into virions as an already-truncated
form. This indicates that the cleavage by vPR is specific
for mA3.
We next examined the cleavage of human-murine chi-
meras as shown in Figure 3A to determine the exact
cleavage site in mA3. Because chimeras containing a
human linker region flanked by the two catalytic sites
(chimeras 1, 2, 5, 8, and 9) was cleaved even in producer
cells, as seen with hA3G, and incorporated into virions,
we could not make any assessment about these
Current Biology
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(A) mA3G was cleaved at the site in the linker region flanked by the two catalytic sites. A schematic figure of human-murine chimera mutants is
shown. A plus sign indicates the presence of the cleaved product only in VLPs, whereas a minus sign indicates the absence of the cleaved prod-
uct. NA indicates ‘‘not assessed’’ because of the presence of a nonspecific cleaved product even in producer cell lysates. Capital letters in
chimera names indicate two catalytic sites. h(H) is for human, and m(M) is for murine. An arrow indicates a predicted cleavage site.
(B) mA3Dexon5 was not cleaved in virions and showed more antiviral activity on MLV. MLV reporter viruses were prepared by cotransfection of
pDON/Luc plus pVSV-G and pMLVg/p with the indicated amounts of expression vectors for hA3G, mA3wt, and mA3Dexon5. The infectivity of
these viruses was presented as the percentage infectivity relative to that of MLV without expression of A3 proteins (top panel). Precipitated vi-
rions were subjected to immunoblotting with HA (middle panel) and MLV Gag (bottom panel) mAbs. A filled arrowhead indicates mA3; a filled
arrowhead with an asterisk indicates a truncated form of mA3; an open arrowhead indicates hA3G; and an arrow with an asterisk indicates p30CA.
(C) The mutants that were not cleaved in virions showed more antiviral activity on MLV. MLV reporter viruses were prepared by cotransfection of
pDON/Luc plus pVSV-G and pMLVg/p with expression vectors for hA3G, mA3wt, mA3Dexon5, and the indicated mutants. The infectivity of these
viruses was presented as described above (top panel). Precipitated virions were subjected to immunoblotting with HA (middle panel) and MLV
Gag (bottom panel) mAbs. A filled arrowhead indicates mA3; a filled arrowhead with an asterisk indicates a truncated form of mA3; an open
arrowhead indicates hA3G; and an arrow with an asterisk indicates p30CA.chimeras (data not shown). In contrast, chimeras 3, 4, 7,
and 10 had a cleaved product only in VLPs. Taking this
information together with the size of a cleaved product,
we predicted that the cleavage site was located in the
linker region of mA3 (Figure 3A, arrow). Mice possess
two types of A3: a full-length form (mA3wt) and an alter-
native splicing form (mA3Dexon5). We and others re-
ported that mA3Dexon5 shows more antiviral activity
(10%–20%) on MLV as well as HIV-1 than mA3wt (Fig-
ure 3B; data not shown). Because the region encoded
by exon5 contained the predicted cleavage site of
mA3, we tested the cleavage of mA3Dexon5 in virions.
The truncated form was not detected in virionpreparation with mA3Dexon5 (middle panel, lanes 3
and 6), and its absence resulted in more incorporation
of mA3Dexon5 into MLV virions. These findings suggest
that mA3Dexon5 possesses more antiviral activity on
MLV and HIV-1 than mA3wt because it is not cleaved
by vPR and that the amount of incorporated mA3 corre-
sponds to its antiviral activity. Because exon5 encoded
amino acids from 199 to 231, we predicted a MLV and
HIV-1 vPR cleavage site between Leu-217 and Thr-
218. We prepared several mutants with a mutation on
Thr-218 and tested their cleavage in virions and their an-
tiviral activity on MLV. A truncated form was detected in
virion preparation with T218S, T218A, and T218E but not
Escape of MLV from Murine APOBEC3
1569in that with T218Y and T218P (Figure 3C). Antiviral activ-
ity of these mutants clearly correlated with their cleav-
age; T218Y and T218P showed more activity than other
mutants with a cleaved form. This suggests that vPR
cleaves mA3 directly between Leu-217 and Thr-218.
In this study, we demonstrate that MLV escapes from
an antiretroviral host factor A3 by two distinct novel
mechanisms: exclusion by vRNA and cleavage by vPR.
This is quite intriguing because a simple retrovirus is
resistant to its cognate A3 by using not an accessory
protein like HIV-1 Vif but by using its basic structural el-
ements such as vRNA and vPR. We suggest that each
virus has its own strategy to protect itself from A3 pro-
teins and that these novel mechanisms might be used
by other viruses that do not possess Vif-like proteins.
We demonstrate that mA3 can be incorporated into
MLV VLPs by binding to MLV Gag and that MLV vRNA
specifically excludes mA3 from MLV virions by inhibiting
its binding to MLV Gag. This specific exclusion might be
attributable to the sites responsible for binding of A3
and vRNA in MLV Gag NC. HIV-1 Gag NC has two Zinc
domains responsible for vRNA binding, whereas the
binding site of hA3G is determined around the N-termi-
nal region of NC [14, 17]. In contrast, MLV Gag NC pos-
sesses only one Zinc finger domain for vRNA binding,
and this domain might be overlaid by the binding site
for A3 proteins. Further study on the A3 binding site in
NC should be performed. We also demonstrate that
not only mA3 but also hA3G is excluded from MLV vi-
rions by vRNA and that the exclusion of mA3 is more
efficient than that of hA3G. There have been controver-
sies about the incorporation of mA3 into MLV virions
and the antiviral activity of hA3G on MLV. The report
by the Landau laboratory first showed no anti-MLV ac-
tivity of hA3G and mA3 despite their incorporation into
MLV virions [6]. In contrast, we and others demonstrated
that hA3G shows anti-MLV activity by being incorpo-
rated into MLV virions, whereas mA3 cannot inhibit
MLV because it is not incorporated into virions [2, 3,
13]. We assume that these discrepancies might origi-
nate from differences in amounts of transfer vectors
used in each study. The greater the amount of transfer
vectors transfected, the more A3 proteins are excluded
from MLV virions, resulting in less anti-MLV activity.
Using a replication competent MLV system, the Cullen
laboratory showed no incorporation into MLV virions
and no anti-MLV activity of mA3 [19]; these results also
support our data.
We also demonstrate that mA3 is specifically cleaved
in MLV and HIV-1 but not in HTLV-1. We previously dem-
onstrated that deletion mutants of hA3 easily lose their
antiviral activity because of loss of dimerization activity
[4]. We also confirmed this notion by conducting exper-
iments that used mA3 deletion mutants (Figure S4). The
experiments with packaging vector mutants and HIV-1
PIs show that vPR is involved in this cleavage. Although
we cannot show the direct cleavage of purified mA3 by
vPR because preparation of purified mA3 is quite diffi-
cult, the experiment with human-murine chimeras en-
ables us to determine that the candidate cleavage site
is located in the linker region flanked by the two active
sites. Furthermore, the experiment with mA3 mutants,
which have a mutation on the predicted cleavage site,
clearly shows the direct cleavage by vPR. We and otherspreviously reported that mA3Dexon5 has more antiviral
activity on MLV and HIV-1. However, the reason for
this has been unclear. mA3Dexon5 is excluded from
virions to similar extents as mA3wt (Figure S3) but can-
not be cleaved by vPR, which results in more antiviral
activity on both viruses. These findings suggest that
the cleavage mechanism confers 10%–20% of the resis-
tance of MLV to mA3 (Figure 3B) and that the remaining
resistance is attributed to the exclusion mechanism. In
light of these results, we conclude that exclusion of
mA3 by vRNA is the main mechanism for the resistance
of MLV to mA3 (Figure 4).
Simple retroviruses are becoming resistant to their
cognate A3 by using vRNA and vPR. They have evolved
to efficiently replicate in their host cells, perhaps
through changes in the structure of Gag NC. Such
changes may have resulted in the loss of the retrovi-
ruses’ resistance to A3, they might have then had to
obtain new genes such as vif and bet to antagonize
A3. On the other hand, from the aspect of host cells,
mA3Dexon5 can protect itself from vPR. Through the
APOBEC family, these findings give us new insight into
how battles between our intrinsic immunity and viruses
have led to the evolution of our innate immune system
and should help us to develop new strategies for con-
trolling viral infection.
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